TREM2 in MASH: integrating lipid metabolism and immune response

TREM2 in MASH: integrating lipid metabolism and immune response

Metabolic dysfunction-Associated Steatohepatitis (MASH), a progressive liver disease characterized by disturbances of lipid metabolism and chronic inflammation response in liver has become the most prevalent chronic liver diseases worldwide. Recent single-cell transcriptomic studies in both humans a...

Full description

Saved in:

Bibliographic Details
Main Authors:	Shuyi Shi, Yangyang Zhou, Haiming Zhang, Junli Zhang
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2025-06-01
Series:	Frontiers in Immunology
Subjects:	metabolic dysfunction -associated steatohepatitis (MASH) triggering receptor expressed on myeloid cells-2 (TREM2) lipid-associated macrophages (LAMs) lipid metabolism immune response
Online Access:	https://www.frontiersin.org/articles/10.3389/fimmu.2025.1604837/full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

MicroRNA-26b protects against MASH development in mice and can be efficiently targeted with lipid nanoparticles
by: Linsey Peters, et al.
Published: (2025-04-01)

TREM2-mediated regulation of microglial activity: a promising target for the treatment of ischemic stroke
by: Haihan Yu, et al.
Published: (2025-07-01)

Identification of biomarkers for the diagnosis in colorectal polyps and metabolic dysfunction-associated steatohepatitis (MASH) by bioinformatics analysis and machine learning
by: Ying Geng, et al.
Published: (2024-11-01)

Gelsolin's Protective Role in MASH through F‐Actin Regulation and P53 Degradation
by: Yiwei Lu, et al.
Published: (2025-06-01)

FDA’s approval of resmetirom (Rezdiffra): a breakthrough in MASH management
by: Muhammad Mazhar Azam, et al.
Published: (2024-12-01)

TREM2 and sTREM2 in Alzheimer’s disease: from mechanisms to therapies
by: Lianshuai Zhang, et al.
Published: (2025-04-01)

Salsalate improves the anti-tumor efficacy of lenvatinib in MASH-driven hepatocellular carcinoma
by: Evangelia E. Tsakiridis, et al.
Published: (2025-05-01)

Chronic administration of a cannabis-derived mixture at an antihyperalgesic dose does not significantly enhance hepatotoxicity or the development of metabolic dysfunction-associated steatohepatitis in male mice
by: Kim B. Pedersen, et al.
Published: (2025-05-01)

Identification and validation of efferocytosis-related biomarkers for the diagnosis of metabolic dysfunction-associated steatohepatitis based on bioinformatics analysis and machine learning
by: Chenghui Cao, et al.
Published: (2024-10-01)

The Nb4C3 MXenzyme Attenuates MASH by Scavenging ROS in a Mouse Model
by: He S, et al.
Published: (2025-04-01)

Macrophage‐Hepatocyte Circuits Mediated by Grancalcin Aggravate the Progression of Metabolic Dysfunction Associated Steatohepatitis
by: Tian Su, et al.
Published: (2024-11-01)

Machine Learning-Based Non-Invasive Prediction of Metabolic Dysfunction-Associated Steatohepatitis in Obese Patients: A Retrospective Study
by: Jie Chen, et al.
Published: (2025-04-01)

Resmetirom in the management of metabolic associated steatohepatitis (MASH): a review of efficacy and safety data from clinical trials
by: Ikponmwosa Jude Ogieuhi, et al.
Published: (2025-06-01)

TREM2 affects DAM-like cell transformation in the acute phase of TBI in mice by regulating microglial glycolysis
by: Lin Wang, et al.
Published: (2025-01-01)

Expression changes and functional role of GPR110 in metabolic dysfunction-associated steatohepatitis
by: Ting HONG, et al.
Published: (2025-06-01)

Correspondence to editorial on “GOLM1 promotes cholesterol gallstone formation via ABCG5-mediated cholesterol efflux in MASH livers”
by: Yi-Tong Li, et al.
Published: (2025-04-01)

Myeloid TGF-β signaling shapes liver macrophage heterogeneity and metabolic liver disease pathogenesis
by: Ziyi Meng, et al.
Published: (2025-08-01)

Bridging the gap: The GOLM1-OPN-ABCG5 axis in MASH and gallstone disease: Editorial on “GOLM1 promotes cholesterol gallstone formation via ABCG5-mediated cholesterol efflux in MASH livers”
by: Nahee Hwang, et al.
Published: (2025-04-01)

Validation of the diagnostic accuracy of the acFibroMASH index for at-risk MASH in patients with metabolic dysfunction-associated steatotic liver disease
by: Yunfei Wu, et al.
Published: (2025-03-01)

Genetic depletion of adipose-derived Isthmin-1 causes hepatic steatosis
by: Saranya C. Reghupaty, et al.
Published: (2025-08-01)

Therapeutic Strategies for MASH: An Update on Drug Candidates Under Investigation in Late-Phase Clinical Trials
by: Samuel Dinerman, et al.
Published: (2025-01-01)

Combination Therapy of Half-Dose Resmetirom and Metformin Attenuates Metabolic Dysfunction-Associated Steatohepatitis Through Improving Cholesterol Metabolism and Inflammation
by: Wenxiu Liu, et al.
Published: (2025-05-01)

BMDM-derived ORP8 suppresses lipotoxicity and inflammation by relieving endoplasmic reticulum stress in mice with MASH
by: Yi Chen, et al.
Published: (2025-05-01)

Hepatic immune environment differences among common mouse strains in models of MASH and liver cancer
by: Patrick Huang, et al.
Published: (2025-05-01)

TRIM25‐Mediated INSIG1 Ubiquitination Promotes MASH Progression Through Reprogramming Lipid Metabolism
by: Hao Zhang, et al.
Published: (2025-06-01)

Targeting lipid metabolism of macrophages: A new strategy for tumor therapy
by: Nan Shao, et al.
Published: (2025-02-01)

Identification of Glycolysis-Related Genes in MAFLD and Their Immune Infiltration Implications: A Multi-Omics Analysis with Experimental Validation
by: Jiawei Chen, et al.
Published: (2025-07-01)

Lipid droplet‐dependent fatty acid metabolism controls the immune suppressive phenotype of tumor‐associated macrophages
by: Hao Wu, et al.
Published: (2019-10-01)

Mechanistic insights into curcumin’s role in modulating autophagy and redox imbalance in experimentally induced MASH
by: Eman A. Elkordy, et al.
Published: (2025-12-01)

Qingrehuoxue formula enhances anti-PD-1 immunotherapy in NSCLC by remodeling the tumor immune microenvironment via TREM2 signaling
by: Bin-bin Li, et al.
Published: (2025-07-01)

Development of a novel diagnostic model to monitor the progression of metabolic dysfunction-associated steatotic liver disease to hepatocellular carcinoma in females
by: Xiaoning Gan, et al.
Published: (2024-12-01)

A Comprehensive Assessment of Liver Transplant Trends and Outcomes Among Adults With Steatotic Liver Disease in the U.S.
by: Shyam Patel, et al.
Published: (2025-01-01)

Molecular spectroscopy of blood plasma differentiates metabolic dysfunction-associated steatohepatitis from steatosis
by: Barbora Nováková, et al.
Published: (2025-08-01)

Understanding Why Metabolic-Dysfunction-Associated Steatohepatitis Lags Behind Hepatitis C in Therapeutic Development and Treatment Advances
by: Caesar Ferrari, et al.
Published: (2024-10-01)

TREM2+ macrophages: a key role in disease development
by: Xinxin Wang, et al.
Published: (2025-04-01)

Proteome of granulosa cells lipid droplets reveals mechanisms regulating lipid metabolism at hierarchical and pre-hierarchical follicle in goose
by: Xin Yuan, et al.
Published: (2025-03-01)

Unraveling the role of GOLM1-OPN-ABCG5 axis in MASH: Editorial on “GOLM1 promotes cholesterol gallstone formation via ABCG5-mediated cholesterol efflux in MASH livers”
by: Yoon-su Ha, et al.
Published: (2025-04-01)

Decompensated MASH-Cirrhosis Model by Acute and Toxic Effects of Phenobarbital
by: Nico Kraus, et al.
Published: (2024-10-01)

Correlation Between Lipid Accumulation Product and Metabolic Dysfunction-Associated Steatotic Liver Disease in Chinese Adults with Type 2 Diabetes Mellitus
by: Liu W, et al.
Published: (2025-06-01)

Comprehensive profiling of candidate biomarkers and immune infiltration landscape in metabolic dysfunction-associated steatohepatitis
by: Zhangliu Jin, et al.
Published: (2025-06-01)